Simultaneous administration of thromboxane A2- and serotonin S2-receptor antagonists markedly enhances thrombolysis and prevents or delays reocclusion after tissue-type plasminogen activator in a canine model of coronary thrombosis.
- 1 April 1989
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 79 (4) , 911-919
- https://doi.org/10.1161/01.cir.79.4.911
Abstract
Dynamic changes of the thrombus after its formation due to platelet activation may affect the speed of thrombolysis. In the present study, we wanted to evaluate the role played by thromboxane A2 (TXA2) and serotonin (5HT) in mediating platelet activation during lysis of intracoronary thrombi with human recombinant tissue-type plasminogen activator (t-PA). Coronary thrombi were induced in 26 anesthetized, open-chest dogs by inserting a copper coil into the left anterior descending coronary artery (LAD). LAD blood flow was monitored throughout the experiment by means of a Doppler flow probe placed proximally to the coil. Presence of the thrombus was documented for 30 minutes. The dogs were then assigned to one of four groups as follows: group 1 dogs (n = 8), serving as controls, received a bolus of heparin (200 units/kg) and a bolus of t-PA (80 micrograms/kg) followed by a continuous infusion (8 micrograms/kg/min) for up to 90 minutes or until reperfusion was achieved; group 2 dogs (n = 10) received, immediately before heparin and t-PA, an intravenous bolus of SQ29548 (SQ) (0.4 mg/kg, a selective TXA2-receptor antagonist) and LY53857 (LY) (0.2 mg/kg, a selective serotonin S2-receptor antagonist); group 3 dogs (n = 7) received, before heparin and t-PA, an intravenous bolus of SQ alone (0.4 mg/kg); and group 4 dogs (n = 7) received, before heparin and t-PA, an intravenous bolus of LY alone (0.2 mg/kg). After thrombolysis, all dogs were monitored for 90 minutes or until a persistent reocclusion occurred.(ABSTRACT TRUNCATED AT 250 WORDS)This publication has 34 references indexed in Scilit:
- Local platelet activation causes vasoconstriction of large epicardial canine coronary arteries in vivo. Thromboxane A2 and serotonin are possible mediators.Circulation, 1989
- Synergism of platelet-aggregating agents. Role of elevation of cytoplasmic calcium.Journal of Clinical Investigation, 1987
- Iliac artery mural thrombus formation. Effect of antiplatelet therapy on 111In-platelet deposition in baboons.Arteriosclerosis: An Official Journal of the American Heart Association, Inc., 1986
- Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.Journal of Clinical Investigation, 1986
- Effects of a thromboxane synthetase inhibitor and a thromboaxane antagonist on release and activity of thromboxane A2 and prostaglandin in vitroProstaglandins, 1985
- Effects of the selective thromboxane synthetase inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries.Circulation, 1984
- Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomographyThe American Journal of Medicine, 1982
- Positive Interaction between Agonists in the Aggregation Response of Human Blood Platelets: Interaction between ADP, Adrenaline and VasopressinBritish Journal of Haematology, 1980
- Synchronized pulsed Doppler blood flow and ultrasonic dimension measurement in conscious dogsUltrasound in Medicine & Biology, 1978
- Inhibition of plasmin by normal and antiplasmin-depleted human plasmaThrombosis Research, 1976